No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $8
Promising Clinical and Financial Prospects for SCYNEXIS: A Comprehensive Buy Rating Analysis
Express News | Scynexis Inc - Cash Runway Exceeds Two Years
Express News | Scynexis : GSK Will Also Pay Mid-Single Digit to Mid-Teen Digit Tiered Royalties on Totality of Ibrexafungerp Sales Across All Indications
Express News | Scynexis Inc - Milestone Payment Triggered by Clinical Study Reports
Express News | Scynexis : Eligible for Additional $323 Million in Milestone Payments
TrytosaveabitOP : Scynexis : GSK Will Also Pay Mid-Single Digit to Mid-Teen Digit Tiered Royalties on Totality of Ibrexafungerp Sales Across All Indications